A. FURTHER INFORMATION ABOUT OUR GROUP

1. Establishment of Our Company

Our Company was established as a limited liability company in the PRC on November 1, 2007 and was converted into a joint stock limited company on July 29, 2021. Our registered office is located at 23AF, Building 3, Zhongke Research and Development Park, No. 009 Gaoxin South 1st Road, Gaoxin Community, Yuehai Subdistrict, Nanshan District, Shenzhen, Guangdong Province, PRC.

Our Company has established a place of business in Hong Kong at 40th Floor, Dah Sing Financial Centre, No. 248 Queen's Road East, Wanchai, Hong Kong and has been registered as a non-Hong Kong company under Part 16 of the Companies Ordinance on January 2, 2026. Ms. Suen Ka Yan (孫嘉恩) has been appointed as our authorized representative for acceptance of service of process and notices in Hong Kong whose correspondence address is the same as our place of business in Hong Kong.

As our Company is established in the PRC, our corporate structure and Articles of Association are subject to the relevant laws and regulations of the PRC. A summary of the relevant provisions of our Articles of Association is set out in "Appendix IV – Summary of Articles of Association."

2. Changes in the Share Capital of Our Company

Save as disclosed in "History, Development and Corporate Structure," there has been no change in the share capital of our Company within the two years immediately preceding the date of this document.

3. Change in the Share Capital of Our Subsidiaries

A summary of the corporate information and the particulars of our subsidiaries are set out in the Accountants' Report.

The following alterations in the total share capital of our subsidiaries have taken place within the two years preceding the date of this Document:

(1) On January 7, 2025, Future Health Netherlands B.V. was established in the Netherlands for the overseas sale of products, with an issued and paid-up capital of 5,000 Euros and principally engaged in overseas product sales activities.

(2) On March 26, 2024, FUTURE HEALTH TECHNOLOGY PTE. LTD. was established as a private company limited by shares in Singapore for the overseas sale of products, with 50,000 shares and principally engaged in overseas product sales activities.

(3) On August 9, 2024, Future Wearable Technology (Foshan) Co., Ltd. (未來穿戴技術(佛山)有限公司) was established as a limited company in the PRC with an initial registered capital of RMB5,000,000.

(4) On August 22, 2024, FUTURE HEALTH TECHNOLOGY SDN. BHD. was established in Malaysia for the overseas sale of products, with a registered capital of 1,000 Malaysian Ringgit and principally engaged in overseas product sales activities.

(5) On September 4, 2024, PT FUTURE HEALTH TECHNOLOGY was established in Indonesia for the overseas sale of products, with an authorized share capital of IDR11,000,000,000 and principally engaged in overseas product sales activities.

(6) On September 13, 2024, Future Health Japan Co., Ltd. (未來健康日本株式會社) was established in Japan as a joint stock company (kabushiki kaisha) for the overseas sale of products, with a share capital of JPY5,000,000 and principally engaged in overseas product sales activities.

(7) On October 30, 2024, Future Wearable (Foshan) Sales Co., Ltd. (未來穿戴(佛山)銷售有限公司) was established as a limited company in the PRC with an initial registered capital of RMB5,000,000.

(8) On July 4, 2025, OTO TECHNOLOGY LIMITED was incorporated as a company with liability limited by shares in the British Virgin Island as an investment holding company, with 50,000 shares to serve as an investment holding company of our Group.

(9) On July 15, 2025, OTO Health Science & Technology (Shenzhen) Co., Ltd. (歐拓健康科技(深圳)有限公司) was established as a limited company in the PRC with an initial registered capital of RMB5,000,000.

(10) On March 23, 2026, Future Wisdom (Shenzhen) Pet Technology Co., Ltd. (未來智慧(深圳)寵物科技有限公司) was established as a limited company in the PRC with an initial registered capital of RMB2,000,000.

Save as disclosed above, there has been no alteration in the share capital of any of our subsidiaries within the two years immediately preceding the date of this Document.

4. Resolutions of Our Shareholders

Pursuant to the resolutions passed at a duly convened general meeting of our Shareholders held on December 5, 2025, our Shareholders resolved that, among others:

(a) the issuance of H Shares with a nominal value of RMB1.00 each and such H Shares being **[REDACTED]** on the Stock Exchange;

(b) the number of H Shares to be issued pursuant to the **[REDACTED]** shall not be more than **[REDACTED]**% of the total issued share capital of the Company as enlarged by the **[REDACTED]** (without taking into account of any H Shares which may be issued upon the exercise of the **[REDACTED]**), and the grant to the **[REDACTED]** (or their representatives) of the **[REDACTED]** of not more than **[REDACTED]**% of the number of H Shares initially available under the **[REDACTED]**;

(c) subject to the filing procedure with the CSRC, upon the completion of the **[REDACTED]**, **[REDACTED]** Unlisted Shares held by existing Shareholders will be converted into H Shares on a one-for-one basis;

(d) subject to the completion of the **[REDACTED]**, the grant of a general mandate to our Board to allot and issue Shares or sell and/or transfer treasury Shares at any time within a period up to the date of the conclusion of the next annual general meeting of the Shareholders or the date on which the Shareholders pass a special resolution to revoke or change such mandate, whichever is earlier, upon such terms and conditions and for such purposes and to such persons as our Board in their absolute discretion deem fit, and to make necessary amendments to the Articles of Association, provided that, the number of Shares to be issued shall not exceed 20% of the number of the Shares in issue (excluding any Treasury Shares) as at the **[REDACTED]**;

(e) subject to the completion of the **[REDACTED]**, the adoption of the Articles of Association which shall become effective on the **[REDACTED]**, and authorization to our Board to amend the Articles of Association to the extent necessary for the purpose of the **[REDACTED]**; and

(f) authorization of our Board or its authorized individual(s) to deal with all matters relating to the **[REDACTED]** and the **[REDACTED]**.

5. Restriction on Share Repurchase

For details of the restrictions on share repurchase by our Company, see "Appendix IV – Summary of Articles of Association."

B. FURTHER INFORMATION ABOUT OUR BUSINESS

1. Summary of Material Contract

We have entered into the following contract (not being contract entered into in the ordinary course of business) within the two years immediately preceding the date of this document that is or may be material:

(a) the **[REDACTED]**.

2. Intellectual Property Rights

(a) Trademarks

As of the Latest Practicable Date, we had registered the following trademarks which we considered to be material to our business.

No.	Trademark	Owner
1.		The Company
2.		The Company
3.		The Company
4.		The Company
5.		The Company
6.		The Company
7.		The Company
8.		The Company
9.		The Company
10.		The Company
11.		The Company
12.		The Company
13.		The Company
14.		The Company
15.		The Company

(b) Patents

As of the Latest Practicable Date, we had registered the following patents which we considered to be material to our business.

No.	Patent name	Registration No.	Owner	Registration date	Registration place
1.	Blood pressure measuring device, apparatus, electronic equipment and storage medium	ZL202410120921.5	the Company	January 29, 2024	PRC
2.	Traction pillow	ZL202321933258.8	the Company	July 20, 2023	PRC
3.	Tremor massage control method, apparatus, massage device, electronic equipment and storage medium	ZL202310036191.6	the Company	January 6, 2023	PRC
4.	Sleep aid device and its control method	ZL202211706106.4	the Company	December 29, 2022	PRC
5.	Central arterial pressure waveform fitting method, monitoring apparatus and watch device	ZL202211529875.1	the Company	November 30, 2022	PRC
6.	Blood pressure measuring method, apparatus, smartwatch, equipment, medium and program product	ZL202211535465.8	the Company	November 30, 2022	PRC
7.	Massage device	ZL202211288352.2	the Company	October 20, 2022	PRC
8.	Absorbent cotton and steam eye massage device	ZL202210109587.4	the Company	January 28, 2022	PRC
9.	Pulse signal output method, apparatus, electric pulse massage device and storage medium	ZL202111630685.4	the Company	December 28, 2021	PRC
10.	Massage control method and apparatus, electronic equipment and computer-readable storage medium	ZL202111196363.3	the Company	October 13, 2021	PRC

No.	Patent name	Registration No.	Owner	Registration date	Registration place
11.	Ultrasonic therapy device output control method and ultrasonic therapy device	ZL202110921484.3	the Company	August 11, 2021	PRC
12.	Laser therapy device output control method and laser therapy device	ZL202110902572.9	the Company	August 6, 2021	PRC
13.	Fascia massage device	ZL202110320826.6	the Company	March 25, 2021	PRC
14.	Eye massage device	ZL202023332111.2	the Company	December 30, 2020	PRC
15.	Neck-hanging massage device	ZL202110530461.X	the Company	May 14, 2021	PRC

(c) Domain Names

As of the Latest Practicable Date, we had registered the following internet domain names which we considered to be material to our business:

No.	Domain name	Owner	Expiry date
1.	skg.com	Our Company	June 10, 2029
2.	gdiskg.cn	Our Company	April 14, 2026
3.	becohealth.com	Our Company	June 15, 2026
4.	skghn.cn	Future Hainan	November 24, 2026

C. FURTHER INFORMATION ABOUT OUR DIRECTORS AND SUBSTANTIAL SHAREHOLDERS

1. Particulars of Directors' Service Contracts

We have entered into a service contract with each of our Directors which contains provisions in relation to, among others, term of service and termination. The service contracts may be renewed in accordance with our Articles of Association and the applicable rules.

Save as disclosed in "Directors and Senior Management" and above, we have not entered into, and do not propose to enter into, any service contracts with any of our Directors in their respective capacities as Directors (excluding agreements expiring or determinable by any member of our Group within one year without payment of compensation other than statutory compensation).

2. Remuneration of Directors

Save as disclosed in "Directors and Senior Management" and Note 8 to the Accountants' Report in Appendix I, none of our Directors received other remuneration or benefits in kind from our Company during the three years ended December 31, 2025.

3. Disclosure of Interests

Interests and short positions of our Directors and chief executive in the Shares and underlying Shares of our Company and our associated corporation

Save as disclosed in "Substantial Shareholders" and below, immediately following the completion of the **[REDACTED]** (assuming the **[REDACTED]** is not exercised and no additional Shares are issued under the Share Option Schemes) and the conversion of the Unlisted Shares into H Shares, so far as our Directors are aware, none of our Directors or chief executive will have any interest and/or short position (as applicable) in the Shares, underlying Shares or debentures of our Company or our associated corporation (within the meaning of Part XV of the SFO) which will be required to be notified to our Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they are taken or deemed to have under such provisions of the SFO) or which will be required, pursuant to Section 352 of the SFO, to be entered in the register referred to therein, or which will be required, pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules to be notified to our Company and the Stock Exchange, once the H Shares are **[REDACTED]** on the Stock Exchange.

Name	Position	Capacity/ Nature of interest	Description of Shares[1]	Number of Shares	Approximate percentage of shareholding in the Share capital of our Company as of the Latest Practicable Date[1]	Approximate percentage of shareholding in the total Share capital of our Company immediately after completion of the [REDACTED] (assuming the [REDACTED] is not exercised and no additional Shares are issued under the Share Option Schemes)[2]	Approximate Percentage of shareholding in the H Shares immediately after completion of the [REDACTED] (assuming the [REDACTED] is not exercised and no additional Shares are issued under the Share Option Schemes)[3]
					(%)	*(%)*	*(%)*
Mr. Liu	Executive Director	Beneficial interest	H Shares	31,748,364	8.82	**[REDACTED]**	**[REDACTED]**
		Interest in controlled corporation; Interest of spouse; interest jointly held with another person[4][5][6]	H Shares	277,651,636	77.13	**[REDACTED]**	**[REDACTED]**
Mr. Hao Qiankun (郝乾坤)	Executive Director, chief financial officer and secretary of the Board	Beneficial interest[7]	H Shares	198,400	0.06	**[REDACTED]**	**[REDACTED]**
Ms. Sheng Jiao (盛姣)	Non-executive Director (employee representative Director)	Beneficial interest[8]	H Shares	113,600	0.03	**[REDACTED]**	**[REDACTED]**

Notes:

(1) For the avoidance of doubt, both Unlisted Shares and H Shares are ordinary Shares in the share capital of our Company, and are considered as one class of Shares. All interests stated are long positions.

(2) The calculation is based on the total number of **[REDACTED]** Shares in issue immediately after completion of the **[REDACTED]** (assuming the **[REDACTED]** is not exercised and no additional Shares are issued under the Share Option Schemes).

(3) The calculation is based on the total number of **[REDACTED]** H Shares in issue immediately after completion of the **[REDACTED]** (assuming the **[REDACTED]** is not exercised and no additional Shares are issued under the Share Option Schemes) after receipt of the filing notice regarding H share "Full circulation" from the CSRC.

(4) Little Swan Ballet is a limited partnership incorporated under the laws of the PRC and is managed by its general partner, Mr. Liu. As such, Mr. Liu is deemed to be interested in the Shares held by Little Swan Ballet under the SFO.

(5) Future Life Investment is a limited liability company incorporated under the laws of the PRC and is owned by Mr. Liu and Ms. Xu, the spouse of Mr. Liu, as to 85.71% and 14.29%, respectively. As such, Mr. Liu and Ms. Xu are deemed to be interested in the Shares held by Future Life Investment under the SFO.

(6) An acting-in-concert agreement was entered into on January 1, 2022, and a supplemental agreement was entered into on November 28, 2025, pursuant to which Mr. Liu, Ms. Xu, Little Swan Ballet and Future Life Investment (i) agreed to act in concert on all proposals and resolutions presented at Board meetings and Shareholders' meetings; and (ii) acknowledged and confirmed that Mr. Liu's decision on such matters shall prevail. As such, each of Mr. Liu, Ms. Xu, Little Swan Ballet and Future Life Investment are deemed to be interested in the Shares each other is interested in under the SFO. For details of the acting-in-concert agreements, see "History, Development and Corporate Structure – Acting-in-concert Arrangements."

(7) Including 9,881 Share Options, 127,219 Share Options and 61,300 Share Options granted to Mr. Hao Qiankun (郝乾坤) pursuant to the 2021 Share Option Scheme, 2024 Share Option Scheme and 2025 Share Option Scheme, entitling him to receive 9,881, 127,219 and 61,300 Shares, respectively, subject to vesting and full exercise of the Share Options granted.

(8) Including 10,200 Share Options, 52,230 Share Options and 51,200 Share Options granted to Ms. Sheng Jiao (盛姣) pursuant to the 2021 Share Option Scheme, 2024 Share Option Scheme and 2025 Share Option Scheme, entitling her to receive 10,200, 52,230 and 51,200 Shares, respectively, subject to vesting and full exercise of the Share Options granted.

Interests of the substantial shareholders in the Shares

Save as disclosed in "Substantial Shareholders," immediately following the completion of the **[REDACTED]** and without taking into account any Shares which may be issued pursuant to the exercise of the **[REDACTED]**, our Directors are not aware of any other person (not being a Director or chief executive of our Company) who will have an interest or short position in our Shares or the underlying Shares which would fall to be disclosed to us and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or who is, directly or indirectly, interested in 10% or more of the issued voting shares of our Company.

Interests of the substantial shareholders in other members of our Group

So far as our Directors are aware, save as disclosed below, as of the Latest Practicable Date, no persons were, directly or indirectly, interested in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of any other members of our Group.

Name of the Subsidiary	Name of the Shareholder	Approximate Percentage of Interest in the Subsidiary
Beike Internet Hospital (Guangdong) Co., Ltd. (倍科互聯網醫院(廣東)有限公司)	Future Life Investment	30%

4. Disclaimers

Save as disclosed in "History, Development and Corporate Structure" and "Business" and above:

(a) none of our Directors or experts named in "Qualifications of Experts" in this section is:

(i) interested in our promotion, or in any assets which have been, within the two years immediately preceding the issue of this document, acquired or disposed of by or leased to any member of our Group, or are proposed to be acquired or disposed of by or leased to any member of our Group;

(ii) materially interested in any contract or arrangement subsisting at the date of this document which is significant in relation to the business of our Group;

(b) none of our Directors or their respective close associates or our Shareholders which to the knowledge of our Directors own more than 5% of the number of our issued Shares (excluding treasury shares) has any interest in our five largest customers or suppliers during the Track Record Period; and

(c) none of our Directors is a director or employee of a company which has an interest or short position in the Shares or underlying Shares of our Company which would fall to be disclosed to our Company pursuant to Divisions 2 and 3 of Part XV of the SFO.

D. SHARE INCENTIVE SCHEMES

1. Employee Incentive Plans

The following is a summary of the principal terms of the Employee Incentive Plans, which were approved and adopted by the Company in November 2020. Given the underlying Shares under the Employee Incentive Plans were either transferred to or had already been issued by the Company to the relevant Employee Incentive Platforms in accordance with terms of the Employee Incentive Plans, there will not be any dilution effect on the issued share capital at our Company. The terms of the Employee Incentive Plans are not subject to the provisions of Chapter 17 of the Listing Rules as the Employee Incentive Plans do not involve the grant of share awards by our Company to subscribe for H Shares after the **[REDACTED]**.

Under the Employee Incentive Plans, Eligible Participants (as defined below) were granted partnership interests in Little Swan Lake and Little Swan Ballet ("**Awards**"), collectively our Employee Incentive Platforms. As of the Latest Practicable Date, Little Swan Lake and Little Swan Ballet held 10,800,000 Shares and 7,200,000 Shares, representing approximately 3.00% and 2.00% of our total issued Shares, respectively.

(a) Purpose

The main purpose of the Employee Incentive Plans is to improve the incentive mechanism of the Group, further enhance the sense of responsibility and mission of the Eligible Participants (as defined below) thereto, promote the continued growth of the performance of the Group, and bring economic benefits to the Eligible Participants while enhancing the value of the Group, so as to realize the common development of the Eligible Participants and the Group.

(b) Administration

Mr. Chen Kai (陳凱) and Mr. Liu, as the respective sole general partner of Little Swan Lake and Little Swan Ballet, are responsible for the administration of the respective Employee Incentive Platform and may exercise the voting rights attaching to the Shares held by them, in accordance with the partnership agreements entered into among the partners of each Employee Incentive Platform.

(c) Eligible Participants

Persons eligible to participate in the Employee Incentive Plans include Directors, senior management, employees, and other personnel of the Group, who have made contribution to the development of the Group (individually and collectively, the "**Eligible Participant(s)**").

(d) Awards

The form of awards available under the Employee Incentive Plans shall be restricted shares that are subject to limitations on transfer and other rights.

(e) Transfer Restrictions

Except for circumstances specified under the terms of the Employee Incentive Plans, no Eligible Participant shall in any way transfer his or her partnership interest in the Employee Incentive Platforms under the Employee Incentive Plans within three years from the **[REDACTED]** ("**Lock-up Period**").

After the Lock-up Period, the disposal of the Awards held by the Eligible Participants shall remain subject to transfer restrictions, which stipulate that the annual disposal of the Awards shall not exceed one-third of the total interests held by the Eligible Participant in the Employee Incentive Platforms.

(f) Details of Awards Granted under the Employee Incentive Plans

Little Swan Lake is a limited partnership established under the laws of the PRC. The general partner of Little Swan Lake is Mr. Chen Kai (陳凱), holding approximately 43.33% of its partnership interest. As of the Latest Practicable Date, the remaining partnership interest was held by 33 limited partners, including (i) three Directors, namely Mr. Liu, Mr. Hao Qiankun (郝乾坤) and Ms. Sheng Jiao (盛姣), holding approximately 13.31%, 16.67% and 1.56% partnership interest, respectively; and (ii) 30 other participants who are current employees of the Group and are Independent Third Parties.

Little Swan Ballet is a limited partnership established under the laws of the PRC. The general partner of Little Swan Ballet is Mr. Liu, holding approximately 49.00% of its partnership interest. As of the Latest Practicable Date, Little Swan Ballet had two limited partners, Mr. Wu Wenxin (吳文新), a former employee of the Group, holding approximately 50% of the partnership interest and Ms. Xun Ruzhen (尋如珍), an employee of our Group, holding approximately 1% partnership interest.

2. Share Option Schemes

The following is a summary of the principal terms of the 2021 Share Option Scheme, 2024 Share Option Scheme and 2025 Share Option Scheme, which were approved and adopted by the Company in September 2021, February 2024 and December 2025, respectively. The Share Option Schemes are not subject to Chapter 17 of the Listing Rules as each of them does not involve any further grant of options or share awards by the Company after the **[REDACTED]**.

(a) Purpose

In order to further improve the corporate governance structure of our Company, strengthen the incentive mechanism, and enhance the sense of responsibility and mission of our management team and key employees, the Share Option Schemes were formulated to ensure the realization of our Company's development strategy and business objectives.

(b) Options

The Share Option Schemes permit the share options approved by the Company (the "**Share Options**").

The term of each Share Option granted under the Share Option Schemes shall be no more than ten (10) years from the date of grant thereof.

(c) Who May Join

Key employees of the Group are eligible to participate in the Share Option Schemes.

(d) Administration

The Share Option Schemes shall be administered by the Board.

(e) Maximum Number of Shares

There is no maximum aggregate number of Shares that may be issued pursuant to Share Options under the 2021 Share Option Scheme, 2024 Share Option Scheme and 2025 Share Option Scheme. Our Company will not grant any further options upon **[REDACTED]**.

(f) Term of the Share Options

In general, the term of each Share Option shall be no more than ten (10) years from the date of grant and shall be the term stated in the award agreement executed by the Company and the grantee (the "**Award Agreement**").

(g) Vesting Schedule and Conditions

The Share Options to be issued to any grantee under the Share Option Schemes shall be subject to the vesting schedule under the terms of the Share Option Schemes and as specified in the Award Agreement of such grantee. A grantee may be required to achieve any performance targets as specified in the Award Agreement of such grantee before any Share Options granted can be vested. The vesting schedule for grantees under the Share Option Schemes is 33%, 33% and 34%, with each portion vesting upon the satisfaction of the performance targets set for the first, second, and third year after granting, respectively.

(h) Exercise of the Share Options, Lock-up and Transfer Restrictions

Subject to applicable laws, any Share Option granted shall be exercisable at such times under the terms of the Share Option Schemes and as specified in the Award Agreement.

The exercise prices under the Share Option Schemes are RMB1.0555, RMB1.78, and RMB1.98 per share for the 2021 Share Option Scheme, 2024 Share Option Scheme and 2025 Share Option Scheme, respectively. These exercise prices, which in principle shall not be lower than the Company's audited net asset value per share for the most recent year at the time of grant, were determined based on an independent pricing method.

The exercise period under 2021 Share Option Scheme and 2024 Share Option Scheme shall be subject to the following lock-up and transfer restrictions:

1. The Share Options that have been vested under the Share Option Schemes shall not be exercised until the **[REDACTED]** of the Company.

2. After the **[REDACTED]**, grantees under the Share Option Schemes shall not dispose of Shares acquired through the exercise of the Share Options within three years from the date of exercise.

3. Upon expiry of such lock-up period, the grantees shall comply with the relevant transfer restriction requirements applicable to the Directors and members of senior management of the Company.

Share Options granted under the 2025 Share Option Scheme shall be exercisable within 12 months after each vesting period.

(i) Outstanding Share Options

2021 Share Option Scheme

As of the Latest Practicable Date, our Company had granted outstanding Share Options under the 2021 Share Option Scheme to 22 grantees to subscribe for an aggregate of 190,162 Shares, representing approximately **[REDACTED]**% of the total issued share capital immediately after completion of the **[REDACTED]** (assuming the **[REDACTED]** is not exercised and no additional Shares are issued under the Share Option Schemes). Among the outstanding options granted, two Directors and member of senior management, one connected person of the Company and 19 grantees who are employees of our Group and are not Directors, member of senior management or connected persons of the Company were granted outstanding options to subscribe for 20,081 Shares, 19,709 Shares, and 150,372 Shares, respectively.

The table below sets forth the details of the outstanding Share Options granted to Directors, member of senior management or connected persons of the Company and other employees of the Group under the 2021 Share Option Scheme:

Name	Position	Address	Number of H Shares underlying the Share Options granted	Date of grant	Exercise Price	Approximate Shareholding Percentage Immediately Following the [REDACTED][(1)]
Directors and Senior Management						
Mr. Hao Qiankun (郝乾坤)	Executive Director, chief financial officer and secretary of the Board	Room 906, Block 17, Phase 3, Kangges Garden, Liangle Road, Daliang Sub-district Office, Shunde District, Foshan City, Guangdong Province, PRC	9,881	September 1, 2021	RMB1.0555	**[REDACTED]**%
Ms. Sheng Jiao (盛姣)	Non-executive Director (employee representative Director)	Building 15, Unit 704, Phase 5, Jiaxin City Garden, Xianghe Road, Daliang Subdistrict Office, Shunde District, Foshan City, Guangdong Province, PRC	10,200	September 1, 2021	RMB1.0555	**[REDACTED]**%
Subtotal	**-**	**-**	***20,081***	**-**	**-**	**[REDACTED]%**

Name	Position	Address	Number of H Shares underlying the Share Options granted	Date of grant	Exercise Price	Approximate Shareholding Percentage Immediately Following the [REDACTED][(1)]
Connected Person						
Lai Zhenyu (賴珍玉)	–	Room 301, Block 12, Haiqin Haoyuan, Qinghua Road, Ronggui Subdistrict, Shunde District, Foshan City, Guangdong Province, PRC	19,709	September 1, 2021	RMB1.0555	**[REDACTED]**%
Subtotal	**–**	**–**	***19,709***	**–**	**–**	**[REDACTED]%**
19 Grantees	–	–	150,372	September 1, 2021	RMB1.0555	**[REDACTED]**%
Total	**–**	**–**	**190,162**	**–**	**–**	**[REDACTED]%**

2024 Share Option Scheme

As of the Latest Practicable Date, our Company had granted outstanding Share Options under the 2024 Share Option Scheme to 52 grantees to subscribe for an aggregate of 1,197,543 Shares, representing approximately **[REDACTED]**% of the total issued share capital immediately after completion of the **[REDACTED]** (assuming the **[REDACTED]** is not exercised and no additional Shares are issued under the Share Option Schemes). Among the outstanding options granted, two Directors and member of senior management, one other connected person of the Company, and 49 grantees who are employees of our Group and are not Directors, member of senior management or connected persons of the Company were granted outstanding options to subscribe for 111,784 Shares, 33,073 Shares and 1,052,686 Shares, respectively.

The table below sets forth the details of the outstanding Share Options granted to Directors, member of senior management or connected persons of the Company and other employees of the Group under the 2024 Share Option Scheme:

Name	Position	Address	Number of H Shares underlying the Share Options granted	Date of grant	Exercise Price	Approximate Shareholding Percentage Immediately Following the [REDACTED][(1)]
Directors and Senior Management						
Mr. Hao Qiankun (郝乾坤)	Executive Director, chief financial officer and secretary of the Board	Room 906, Block 17, Phase 3, Kangges Garden, Liangle Road, Daliang Sub-district Office, Shunde District, Foshan City, Guangdong Province, PRC	79,089	February 5, 2024	RMB1.78	**[REDACTED]**%
Ms. Sheng Jiao (盛姣)	Non-executive Director (employee representative Director)	Building 15, Unit 704, Phase 5, Jiaxin City Garden, Xianghe Road, Daliang Subdistrict Office, Shunde District, Foshan City, Guangdong Province, PRC	32,694	February 5, 2024	RMB1.78	**[REDACTED]**%
Subtotal	**–**	**–**	***111,784***	**–**	**–**	**[REDACTED]%**
Connected Person						
Lai Zhenyu (賴珍玉)	–	Room 301, Block 12, Haiqin Haoyuan, Qinghua Road, Ronggui Subdistrict, Shunde District, Foshan City, Guangdong Province, PRC	33,073	February 5, 2024	RMB1.78	**[REDACTED]**%
Subtotal	**–**	**–**	***33,073***	**–**	**–**	**[REDACTED]%**
49 Grantees	–	–	1,052,686	February 5, 2024	RMB1.78	**[REDACTED]**%
Total	**–**	**–**	**1,197,543**	**–**	**–**	**[REDACTED]%**

2025 Share Option Scheme

As of the Latest Practicable Date, our Company had granted outstanding Share Options under the 2025 Share Option Scheme to 127 grantees to subscribe for an aggregate of 2,933,200 Shares, representing approximately **[REDACTED]**% of the total issued share capital immediately after completion of the **[REDACTED]** (assuming the **[REDACTED]** is not exercised and no additional Shares are issued under the Share Option Schemes). Among the outstanding options granted, two Directors and member of senior management, two other connected person of the Company, and 123 grantees who are employees of our Group and are not Directors, member of senior management, or connected persons of the Company were granted outstanding options to subscribe for 112,500 Shares, 133,400 Shares and 2,687,300 Shares, respectively.

The table below sets forth the details of the outstanding Share Options granted to Directors, member of senior management or connected persons of the Company and other employees of the Group under the 2025 Share Option Scheme:

Name	Position	Address	Number of H Shares underlying the Share Options granted	Date of grant	Exercise Price	Approximate Shareholding Percentage Immediately Following the [REDACTED][(1)]
Directors and Senior Management						
Mr. Hao Qiankun (郝乾坤)	Executive Director, chief financial officer and secretary of the Board	Room 906, Block 17, Phase 3, Kangges Garden, Liangle Road, Daliang Sub-district Office, Shunde District, Foshan City, Guangdong Province, PRC	61,300	December 5, 2025	RMB1.98	**[REDACTED]**%
Ms. Sheng Jiao (盛姣)	Non-executive Director (employee representative Director)	Building 15, Unit 704, Phase 5, Jiaxin City Garden, Xianghe Road, Daliang Subdistrict Office, Shunde District, Foshan City, Guangdong Province, PRC	51,200	December 5, 2025	RMB1.98	**[REDACTED]**%
Subtotal	-	-	*112,500*	-	-	[REDACTED]%

Name	Position	Address	Number of H Shares underlying the Share Options granted	Date of grant	Exercise Price	Approximate Shareholding Percentage Immediately Following the [REDACTED](1)
Connected Persons						
Lai Zhenyu(2) (賴珍玉)	General manager of Future Sunflower	Room 301, Block 12, Haiqin Haoyuan, Qinghua Road, Ronggui Subdistrict, Shunde District, Foshan City, Guangdong Province, PRC	56,200	December 5, 2025	RMB1.98	[REDACTED]%
Xiang Dongdong(3) (向冬冬)	Head of the China marketing center of the Company	No. 6, Xiangjia Group, Hefan Community, Zhanqiao Town, Linxiang City, Hunan Province, PRC	77,200	December 5, 2025	RMB1.98	[REDACTED]%
Subtotal	-	-	*133,400*	-	-	[REDACTED]%
123 Grantees	–	–	2,687,300	December 5, 2025	RMB1.98	[REDACTED]%
Total	-	-	**2,933,200**	-	-	[REDACTED]%

Note:

1. Assuming the **[REDACTED]** is not exercised and no additional Shares are issued under the Share Option Schemes.

2. Lai Zhenyu is the general manager of Future Sunflower. Lai Zhenyu is primarily responsible for the overall management of our production facility.

3. Xiang Dongdong is the head of our marketing center for the China region and is the director and general manager of Future Hainan.

In respect of the outstanding Share Options granted under the Share Option Schemes, we have applied to the Stock Exchange and the SFC, respectively for, (i) a waiver from strict compliance with the disclosure requirements under Rule 17.02(1)(b) of the Listing Rules and paragraph 27 of Appendix DIA to the Listing Rules; and (ii) an exemption under section 342A of the Companies (Winding Up and Miscellaneous Provisions) Ordinance from strict compliance with the disclosure requirements of paragraph 10(d) of Part I of the Third Schedule to the Companies (Winding Up and Miscellaneous Provisions) Ordinance. See "Waivers and Exemptions" for details.

(j) Dilution Effect and Impact on Earnings per Share

Immediately following completion of the **[REDACTED]** (assuming the **[REDACTED]** is not exercised) and assuming full vesting and exercise of all outstanding Share Options under the Share Option Schemes, the dilution effect on our earnings per Share will be diluted by approximately **[REDACTED]**%.

E. OTHER INFORMATION

1. Estate Duty

Our Directors have been advised that no material liability for estate duty is likely to fall on our Company or our subsidiaries.

2. Litigation

As of the Latest Practicable Date, no member of our Group was involved in any litigation, arbitration, administrative proceedings or claims of material importance, and, so far as we are aware, no litigation, arbitration, administrative proceedings or claims of material importance are pending or threatened against any member of our Group.

3. Sole Sponsor

The Sole Sponsor has made an application on behalf of our Company to the Stock Exchange for the **[REDACTED]** of, and permission to deal in, the H Shares to be issued pursuant to **[REDACTED]** and the H Shares to be converted from Unlisted Shares, on the Main Board of the Stock Exchange. The Sole Sponsor will receive an aggregate fee of RMB4.0 million for acting as sole sponsor for the **[REDACTED]**.

The Sole Sponsor satisfies the independence criteria applicable to sponsor set out in Rule 3A.07 of the Listing Rules.

4. Preliminary Expense

As of the Latest Practicable Date, our Company did not incur any material preliminary expense.

5. Promotors

The promoters of our Company are all the then Shareholders as of July 29, 2021 immediately before our conversion into a joint stock limited company. Save as otherwise disclosed in this document, within the two years immediately preceding the date of this document, no cash, securities or other benefit has been paid, allotted or given nor are any proposed to be paid, allotted or given to any promotors of our Company in connection with the **[REDACTED]** or the related transactions described in this document.

6. Qualifications of Experts

The qualifications of the experts who have given opinions or advice in this document are as follows:

Name	Qualification
China Securities (International) Corporate Finance Company Limited	Licensed to conduct Type 1 (dealing in securities) and Type 6 (advising on corporate finance) of regulated activities as defined under the SFO
Ernst & Young	Certified Public Accountants under Professional Accountants Ordinance (Chapter 50 of the Laws of Hong Kong) Registered Public Interest Entity Auditor under Accounting and Financial Reporting Council Ordinance (Chapter 588 of the Laws of Hong Kong)
Grandway Law Offices	Legal advisor to our Company as to PRC law
Jones Lang LaSalle Corporate Appraisal and Advisory Limited	Property valuer
Frost & Sullivan (Beijing) Inc., Shanghai Branch Co.	Industry consultant
Ernst & Young (China) Advisory Limited	Transfer pricing advisor to our Company

7. Consent of Experts

Each of the experts named above has given and has not withdrawn its written consent to the issue of this document with the inclusion of its reports, letters or opinions (as the case may be) and the references to its name included herein in the form and context in which they are included.

As of the Latest Practicable Date, none of the experts named above had any shareholding in any member of our Group or right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in any member of our Group.

8. Stamp Duty

The sale, purchase and transfer of H Shares will be subject to Hong Kong stamp duty. The current rate charged on each of the seller and purchaser is 0.1% of the consideration or, if higher, the fair value of the H Shares being sold or transferred.

9. Binding Effect

This document shall have the effect, if any application is made pursuant hereto, of rendering all persons concerned bound by all the provisions (other than the penal provisions) of sections 44A and 44B of the Companies (Winding Up and Miscellaneous Provisions) Ordinance as far as applicable.

10. Bilingual Document

The English language and Chinese language versions of this document are being published separately in reliance upon the exemption provided by section 4 of the Companies Ordinance (Exemption of Companies and Prospectuses from Compliance with Provisions) Notice (Chapter 32L of the Laws of Hong Kong).

11. Miscellaneous

(a) Save as otherwise disclosed "Financial Information," "History, Development and Corporate Structure" and "**[REDACTED]**," within the two years immediately preceding the issue of this document:

(i) no share or debenture of any member of our Group has been issued or agreed to be issued or is proposed to be issued for cash or as fully or partly paid up otherwise than in cash;

(ii) no share or debenture of any member of our Group is under option or agreed conditionally or unconditionally to be put under option;

(iii) no commissions, discounts, brokerages or other special terms have been granted in connection with the issue or sale of any capital of any member of our Group; and

(iv) no commission has been paid or is payable for subscribing, agreeing to subscribe, procuring or agreeing to procure subscriptions for any shares in or debentures of our Company.

(b) There are no founder or management or deferred shares in our Company.

(c) There is no restriction affecting the remittance of profits or repatriation of capital of our Company into Hong Kong from outside Hong Kong.

(d) There is no arrangement under which future dividends are waived or agreed to be waived.

(e) There are no contracts for the hire or hire purchase of plant to or by our Group for a period of over one year which are substantial in relation to our Group's business.

(f) There have been no interruptions in our business which may have or have had a significant effect on our financial position in the last 12 months.

(g) No part of the equity or debt securities of our Company is listed or dealt in on any stock exchange, and no such listing or permission to deal on any stock exchange other than the **[REDACTED]** is being or is proposed to be sought.

(h) Our Company has no outstanding convertible debt securities or debentures.